By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CSL Behring 

1020 First Avenue
P.O. Box 61501
King of Prussia  Pennsylvania  19406-0901  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009



Company News
CSL Behring Submits Biologics License Application For FDA Approval Of Recombinant Fusion Protein Linking Coagulation Factor IX With Recombinant Albumin (Rix-FP) For Hemophilia B Patients 12/16/2014 8:36:38 AM
Startup Enable Injections Hiring As It Inks Deal With CSL Behring 11/12/2014 6:25:46 AM
CSL Behring Release: Evidence Presented At The 16th Biennial Meeting Of The European Society For Immunodeficiencies (ESID) Supports Individualized Dosing With Hizentra® 10/31/2014 8:32:59 AM
CSL Behring Announces Winners Of Its 13th Annual Gettin' In The Game(SM) Junior National Championship Program 10/29/2014 8:44:34 AM
CSL Behring Signs Strategic Development Agreement With Enable Injections To Market Novel New Drug Delivery Device 10/28/2014 9:26:42 AM
CSL Behring To Create 200 New Jobs In $450 Million Expansion Of Illinois, Australia Sites 10/8/2014 9:00:43 AM
CSL Behring Expands Manufacturing Facility In Kankakee, Illinois To Meet Patients' Growing Needs 9/30/2014 9:22:43 AM
CSL Behring Announces Last Patient Treated In Phase 3 Study Of Fibrinogen Concentrate To Control Bleeding During Aortic Aneurysm Surgery 9/16/2014 8:28:08 AM
CSL Behring Release: Study Suggests C1-INH May Aid In Prevention Of Antibody-Mediated Rejection Following Kidney Transplant 7/30/2014 9:45:37 AM
CSL Behring Announces The 2014 Interlaken Leadership Awards Recipient 6/24/2014 8:26:41 AM